GENE ONLINE|News &
AstraZeneca Acquires Cell Therapy Company in $1 Billion Deal to Develop In Vivo Cancer Treatments
AstraZeneca has announced the acquisition of a cell therapy company in a deal valued at up to $1 billion. The move aims to bolster the development of in vivo cancer therapies and advance the company’s efforts in cell therapy research. This acquisition reflects AstraZeneca’s continued focus on innovative approaches to treating cancer.
The agreement includes provisions for research into *in vivo* treatments, which involve targeting cells directly within the body rather than relying on external manipulation before reintroduction. The investment underscores AstraZeneca’s commitment to exploring cutting-edge therapeutic strategies that could potentially reshape how certain cancers are treated. Further details about the acquired company and its specific contributions to AstraZeneca’s pipeline have not been disclosed at this time.
Date: 17 March, 2025
Newsflash | Powered by GeneOnline AI
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
